UBE announces Phase I clinical trial for SSAO/VAP-1 licensed exclusively to Novo Nordisk
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Ayush is expanding beyond wellness to therapeutic wellness
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries
Additionally, an MoU was signed between the Dental Council of India and Quality Council of India for the assessment and rating of undergraduate dental colleges
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Subscribe To Our Newsletter & Stay Updated